vestarВестник аритмологииJournal of Arrhythmology1561-86412658-7327НАО «Инкарт»10.25760/VA-2018-93-64-72.vestar-122Research ArticleВ ПОМОЩЬ ПРАКТИКУЮЩИМ ВРАЧАМGUIDE TO PRACTITIONERSАНТИТРОМБОТИЧЕСКАЯ ТЕРАПИЯ У БОЛЬНЫХ С ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ ПОСЛЕ ЧРЕСКОЖНОГО КОРОНАРНОГО ВМЕШАТЕЛЬСТВА: ПРИШЛО ВРЕМЯ ОГРАНИЧИТЬСЯ ДВУМЯ ПРЕПАРАТАМИ?ANTITHROMBOTIC THERAPY IN PATIENTS WITH ATRIAL FIBRILLATION FOLLOWING PERCUTANEOUS CORONARY INTERVENTION: IS IT TIME TO BE CONFINED TO DUAL THERAPY?КанорскийС. Г.KanorskyS. G.noemail@neicon.ruФГБОУ ВО Кубанский государственный медицинский университет МЗ РФRussian Federation2018170420190936472Copyright © Канорский С.Г., 20192019Канорский С.Г.Kanorsky S.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vestar.elpub.ru/jour/article/view/122

Представлены основные положения действующих рекомендаций по ведению больных с фибрилляцией предсердий, нуждающихся в антикоагулянтной терапии, после перенесенного чрескожного коронарного вмешательства; обсуждается возможность оптимизации тактики лечения данной категории пациентов с учетом результатов недавних рандомизированных исследований.

Key elements of current guidelines on management of patients with atrial fibrillation and indications to anticoagulant therapy after percutaneous coronary intervention are given; a potential of optimization of treatment strategy of these patients is discussed taking the results of recent randomized studies into account.

фибрилляция предсердийчрескожное коронарное вмешательствоострые коронарные синдромыпрямые оральные антикоагулянтыантитромбоцитарные препаратыatrial fibrillationpercutaneous coronary interventionacute coronary syndromesdirect oral anticoagulantsantiplatelet medicationsReferencesKirchhof P., Benussi S., Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016; 37(38): 2893-2962. doi: 10.1093/eurheartj/ehw210.Kirchhof P., Benussi S., Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016; 37(38): 2893-2962. doi: 10.1093/eurheartj/ehw210.Schömig A., Neumann F.J., Kastrati A. et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 1996; 334(17): 1084-1089. doi: 10.1056/NEJM199604253341702.Schömig A., Neumann F.J., Kastrati A. et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 1996; 334(17): 1084-1089. doi: 10.1056/NEJM199604253341702.Leon M.B., Baim D.S., Popma J.J. et al. A clinical trial comparing three antithrombotic-drug regimens after coronaryartery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. 1998; 339(23): 1665-1671. doi: 10.1056/NEJM199812033392303.Leon M.B., Baim D.S., Popma J.J. et al. A clinical trial comparing three antithrombotic-drug regimens after coronaryartery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. 1998; 339(23): 1665-1671. doi: 10.1056/NEJM199812033392303.Kerneis M., Talib U., Nafee T. et al. Triple Antithrombotic Therapy for Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. Prog Cardiovasc Dis. 2018; 60(4-5): 524-530. doi: 10.1016/j.pcad.2018.01.008.Kerneis M., Talib U., Nafee T. et al. Triple Antithrombotic Therapy for Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. Prog Cardiovasc Dis. 2018; 60(4-5): 524-530. doi: 10.1016/j.pcad.2018.01.008.January C.T., Wann L.S., Alpert J.S. et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014; 64(21): e1-e76. doi: 10.1016/j.jacc.2014.03.022.January C.T., Wann L.S., Alpert J.S. et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014; 64(21): e1-e76. doi: 10.1016/j.jacc.2014.03.022.Angiolillo D.J., Goodman S.G., Bhatt D.L. et al. Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2016 Update. Circ Cardiovasc Interv. 2016; 9(11). doi: 10.1161/circinterventions.116.004395.Angiolillo D.J., Goodman S.G., Bhatt D.L. et al. Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2016 Update. Circ Cardiovasc Interv. 2016; 9(11). doi: 10.1161/circinterventions.116.004395.Lip G.Y., Windecker S., Huber K. et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J. 2014; 35(45): 3155-3179. doi: 10.1093/eurheartj/ehu298.Lip G.Y., Windecker S., Huber K. et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J. 2014; 35(45): 3155-3179. doi: 10.1093/eurheartj/ehu298.Capodanno D., Angiolillo D.J. Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions. Circ Cardiovasc Interv. 2014; 7(1): 113-124. doi: 10.1161/circinterventions.113.001150.Capodanno D., Angiolillo D.J. Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions. Circ Cardiovasc Interv. 2014; 7(1): 113-124. doi: 10.1161/circinterventions.113.001150.Hansen M.L., Sørensen R., Clausen M.T. et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010; 170(16): 1433-1441. doi: 10.1001/archinternmed.2010.271.Hansen M.L., Sørensen R., Clausen M.T. et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010; 170(16): 1433-1441. doi: 10.1001/archinternmed.2010.271.Mega J., Carreras E.T. Antithrombotic therapy: triple therapy or triple threat? Hematology Am Soc Hematol Educ Program. 2012; 2012: 547-552. doi: 10.1182/asheducation-2012.1.547.Mega J., Carreras E.T. Antithrombotic therapy: triple therapy or triple threat? Hematology Am Soc Hematol Educ Program. 2012; 2012: 547-552. doi: 10.1182/asheducation-2012.1.547.Dans A.L., Connolly S.J., Wallentin L. et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation. 2013; 127(5): 634-640. doi: 10.1161/circulationaha.112.115386.Dans A.L., Connolly S.J., Wallentin L. et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation. 2013; 127(5): 634-640. doi: 10.1161/circulationaha.112.115386.Dewilde W.J., Oirbans T., Verheugt F.W. et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013; 381(9872): 1107-1115. doi: 10.1016/S0140-6736(12)62177-1.Dewilde W.J., Oirbans T., Verheugt F.W. et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013; 381(9872): 1107-1115. doi: 10.1016/S0140-6736(12)62177-1.Fiedler K.A., Maeng M., Mehilli J. et al. Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation: The ISAR-TRIPLE Trial. J Am Coll Cardiol. 2015; 65(16): 1619-1629. doi: 10.1016/j.jacc.2015.02.050.Fiedler K.A., Maeng M., Mehilli J. et al. Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation: The ISAR-TRIPLE Trial. J Am Coll Cardiol. 2015; 65(16): 1619-1629. doi: 10.1016/j.jacc.2015.02.050.Gibson C.M., Mehran R., Bode C. et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med. 2016; 375(25): 2423-2434. doi: 10.1056/NEJMoa1611594.Gibson C.M., Mehran R., Bode C. et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med. 2016; 375(25): 2423-2434. doi: 10.1056/NEJMoa1611594.Cannon C.P., Bhatt D.L., Oldgren J. et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med. 2017; 377(16): 1513-1524. doi: 10.1056/NEJMoa1708454.Cannon C.P., Bhatt D.L., Oldgren J. et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med. 2017; 377(16): 1513-1524. doi: 10.1056/NEJMoa1708454.Roffi M., Patrono C., Collet J.P. et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016; 37(3): 267-315. doi: 10.1093/eurheartj/ehv320.Roffi M., Patrono C., Collet J.P. et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016; 37(3): 267-315. doi: 10.1093/eurheartj/ehv320.Bavishi C., Panwar S., Messerli F.H., Bangalore S. Meta-Analysis of Comparison of the Newer Oral P2Y12 Inhibitors (Prasugrel or Ticagrelor) to Clopidogrel in Patients With Non-ST-Elevation Acute Coronary Syndrome. Am J Cardiol. 2015; 116(5): 809-817. doi: 10.1016/j.amjcard.2015.05.058.Bavishi C., Panwar S., Messerli F.H., Bangalore S. Meta-Analysis of Comparison of the Newer Oral P2Y12 Inhibitors (Prasugrel or Ticagrelor) to Clopidogrel in Patients With Non-ST-Elevation Acute Coronary Syndrome. Am J Cardiol. 2015; 116(5): 809-817. doi: 10.1016/j.amjcard.2015.05.058.Valgimigli M., Bueno H., Byrne R.A. et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018; 39(3): 213-260. doi: 10.1093/eurheartj/ehx419.Valgimigli M., Bueno H., Byrne R.A. et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018; 39(3): 213-260. doi: 10.1093/eurheartj/ehx419.Sarafoff N., Martischnig A., Wealer J et al. Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation. J Am Coll Cardiol. 2013; 61(20): 2060-2066. doi: 10.1016/j.jacc.2013.02.036.Sarafoff N., Martischnig A., Wealer J et al. Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation. J Am Coll Cardiol. 2013; 61(20): 2060-2066. doi: 10.1016/j.jacc.2013.02.036.Kereiakes D.J., Yeh R.W., Massaro J.M. et al. Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial. JAMA. 2015; 313(11): 1113-1121. doi: 10.1001/jama.2015.1671.Kereiakes D.J., Yeh R.W., Massaro J.M. et al. Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial. JAMA. 2015; 313(11): 1113-1121. doi: 10.1001/jama.2015.1671.Valgimigli M., Patialiakas A., Thury A. et al. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. J Am Coll Cardiol. 2015; 65(8): 805-815. doi: 10.1016/j.jacc.2014.11.053.Valgimigli M., Patialiakas A., Thury A. et al. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. J Am Coll Cardiol. 2015; 65(8): 805-815. doi: 10.1016/j.jacc.2014.11.053.Ariotti S., Adamo M., Costa F. et al. Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?: A Pre-Specified Analysis From the ZEUS Trial. JACC Cardiovasc Interv. 2016; 9(5): 426-436. doi: 10.1016/ j.jcin.2015.11.015.Ariotti S., Adamo M., Costa F. et al. Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?: A Pre-Specified Analysis From the ZEUS Trial. JACC Cardiovasc Interv. 2016; 9(5): 426-436. doi: 10.1016/ j.jcin.2015.11.015.Steffel J., Verhamme P., Potpara T.S. et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018; 39(16): 1330-1393. doi: 10.1093/eurheartj/ehy136.Steffel J., Verhamme P., Potpara T.S. et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018; 39(16): 1330-1393. doi: 10.1093/eurheartj/ehy136.Mehta S.R., Bainey K.R., Cantor W.J. 2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy. Can J Cardiol. 2018; 34(3): 214-233. doi: 10.1016/j.cjca.2017.12.012.Mehta S.R., Bainey K.R., Cantor W.J. 2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy. Can J Cardiol. 2018; 34(3): 214-233. doi: 10.1016/j.cjca.2017.12.012.Alexander J.H., Becker R.C., Bhatt D.L. et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. 2009; 119(22): 2877-2885. doi: 10.1161/circulationaha.108.832139.Alexander J.H., Becker R.C., Bhatt D.L. et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. 2009; 119(22): 2877-2885. doi: 10.1161/circulationaha.108.832139.Mega J.L., Braunwald E., Mohanavelu S. et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, doubleblind, phase II trial. Lancet. 2009; 374(9683): 29-38. doi: 10.1016/S0140-6736(09)60738-8.Mega J.L., Braunwald E., Mohanavelu S. et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, doubleblind, phase II trial. Lancet. 2009; 374(9683): 29-38. doi: 10.1016/S0140-6736(09)60738-8.Oldgren J., Budaj A., Granger C.B. et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J. 2011; 32(22): 2781-2789. doi: 10.1093/eurheartj/ehr113.Oldgren J., Budaj A., Granger C.B. et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J. 2011; 32(22): 2781-2789. doi: 10.1093/eurheartj/ehr113.Steg P.G., Mehta S.R., Jukema J.W. et al. RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur Heart J. 2011; 32(20): 2541-2554. doi: 10.1093/eurheartj/ehr334.Steg P.G., Mehta S.R., Jukema J.W. et al. RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur Heart J. 2011; 32(20): 2541-2554. doi: 10.1093/eurheartj/ehr334.Alexander J.H., Lopes R.D., James S. et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011; 365(8): 699-708. doi: 10.1056/NEJMoa1105819.Alexander J.H., Lopes R.D., James S. et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011; 365(8): 699-708. doi: 10.1056/NEJMoa1105819.Mega J.L., Braunwald E., Wiviott S.D. et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012; 366(1): 9-19. doi: 10.1056/NEJMoa1112277.Mega J.L., Braunwald E., Wiviott S.D. et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012; 366(1): 9-19. doi: 10.1056/NEJMoa1112277.Bayer A.G. Xarelto Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf. Accessed June 28, 2018.Bayer A.G. Xarelto Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf. Accessed June 28, 2018.Gibson C.M., Pinto D.S., Chi G. et al. Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy. Circulation. 2017; 135(4): 323-333. doi: 10.1161/circulationaha.116.025783.Gibson C.M., Pinto D.S., Chi G. et al. Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy. Circulation. 2017; 135(4): 323-333. doi: 10.1161/circulationaha.116.025783.Kerneis M., Gibson C.M., Chi G. et al. Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial. JACC Cardiovasc Interv. 2018; 11(7): 626-634. doi: 10.1016/j.jcin.2017.11.009.Kerneis M., Gibson C.M., Chi G. et al. Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial. JACC Cardiovasc Interv. 2018; 11(7): 626-634. doi: 10.1016/j.jcin.2017.11.009.Cannon C.P, Bhatt D.L., Oldgren J. et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med. 2017; 377(16): 1513-1524. doi: 10.1056/NEJMoa1708454.Cannon C.P, Bhatt D.L., Oldgren J. et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med. 2017; 377(16): 1513-1524. doi: 10.1056/NEJMoa1708454.Jackson L.R. 2nd, Ju C., Zettler M. et al. Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus Prasugrel From the TRANS-LATE-ACS Study. JACC Cardiovasc Interv. 2015; 8(14): 1880-1889. doi: 10.1016/j.jcin.2015.08.018.Jackson L.R. 2nd, Ju C., Zettler M. et al. Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus Prasugrel From the TRANS-LATE-ACS Study. JACC Cardiovasc Interv. 2015; 8(14): 1880-1889. doi: 10.1016/j.jcin.2015.08.018.Ohman E.M., Roe M.T., Steg P.G. et al. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Lancet. 2017; 389(10081): 1799-1808. doi: 10.1016/S0140-6736(17)30751-1.Ohman E.M., Roe M.T., Steg P.G. et al. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Lancet. 2017; 389(10081): 1799-1808. doi: 10.1016/S0140-6736(17)30751-1.Breet N.J., van Werkum J.W., Bouman H.J. et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA. 2010; 303(8): 754-762. doi: 10.1001/jama.2010.181.Breet N.J., van Werkum J.W., Bouman H.J. et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA. 2010; 303(8): 754-762. doi: 10.1001/jama.2010.181.

The authors declare that there are no conflicts of interest present.